Management guideline for the off-label use of medicine in China (2021)

References

• Clinical Pharmacology Group of Pediatrics Branch of Chinese Medical Association. Editorial board of Chinese journal of pediatrics. expert consensus on off-label medication in Chinese pediatrics. Chin J Pediatr. 2016;54(2):101–103.
   Google Scholar
• Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021–1026.
   Google Scholar
• Zhang B, Li DK, Yang X. Some problems and Countermeasures of usage beyond drug instructions. Chinese J Rheumatol. 2004;08:451–453.
   Google Scholar
• Zhang B, Zheng ZH, Li DK. Unlabeled use of medication (1st ed). 2013; People‘s Health Publishing House.
   Google Scholar
• Hou N. Expert consensus on off-label drug use of Shandong province(2021th). ClinMed J. 2021;19(6):9–40.
   Google Scholar
• Chen M, Liu Z. Expert consensus on clinical severe and pharmaceutical off-label instructions. Pharm Today. 2020;30(8):505–515.
   Google Scholar
• Guangdong Pharmaceutical Association. Expert consensus on pharmacoeconomic evaluation of off-label drug instructions. Pharm Today. 2016;26(10):681–683.
   Google Scholar
• The Central People’s Government of the People’s Republic of China. Law on doctors of the People’s Republic of China. [cited 2021 Dec 23]. Available at: http://www.xinhuanet.com/politics/2021-08/20/c_1127781587.htm.
   Google Scholar
• World Health Organization. WHO handbook for guideline development, (2nd ed). World Health Organization, 2014.
   Google Scholar
• Jiang Z, Zhan S, Jia X, et al. Basic methods and procedures for formulating/revising clinical diagnosis and treatment guidelines. Nat Med J China. 2016;96(4):250–253.
   Google Scholar
• Brouwers MC, Kho ME, Browman GP, et al. AGREE : advancing guideline development, reporting and evaluation in health care. Cmaj. 2010;182(18):E839–42.
   Google Scholar
• Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med. 2017;166(2):128–132.
   Google Scholar
• Chen Y, Wang X, Wang Q, et al. Following the guideline report specification to improve the guideline report quality. Chinese J Int Med. 2018;57(3):168–170.
   Google Scholar
• Chen Y, Ma Y, Zhou Q, et al. Who should participate in the development of clinical practice guidelin? Med J of Peking Union Med Coll Hosp. 2019;10(5):524–530.
   Google Scholar
• Reay T, Berta WB, Kohn MK. What’s the evidence on evidence-based management? Acad Manag Perspect. 2009;23(4):5–18.
   Google Scholar
• Oxford Centre for Evidence-Based Medicine. March 2009. Oxford centre for evidence-based medicine: levels of evidence cited2021 Dec 23]. Available at: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009
   Google Scholar
• Vernooij RW, Alonso-Coello P, Brouwers M, et al. Reporting items for updated clinical guidelines: checklist for the reporting of updated guidelines (Checkup). PLoS Med. 2017;14(1):e1002207.
   Google Scholar
• National Institute for Health and Care Excellence. The guidelines manual. [cited 2021 Dec 23]. Available at: https://www.nice.org.uk/process/pmg6/resources/the-guidelines-manual-pdf-2007970804933
   Google Scholar
• Working Group for CPG Updates. Updating clinical practice guidelines in the national health system: methodology handbook. national health system quality plan of the Spanish ministry of health and social policy. Aragon health sciences institute (I+CS), 2009. Clinical Practice Guidelines in the National Health System: I+CS No. 2007/02-01. [cited 2021 Dec 23]. Available at: https://portal.guiasalud.es/wp-content/uploads/2019/06/manual_actualizacion_gpc_ingles-2.pdf
   Google Scholar
• The central people’s government of the People’s Republic of China. Provisions on the Administration of Pharmaceutical Directions and Labels. [cited 2021 Dec 23]. Available at: http://www.gov.cn/flfg/2006-03/16/content_228465.htm
   Google Scholar
• Gazarian M, Kelly M, McPhee JR, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544–548. 10.5694/j.1326-5377.2006.tb00689.x.
   Google Scholar
• National Institute for Health and Care Excellence. Evidence Summaries: unlicensed and off-label medicines – integrated process statement [Internet]. London: National Institute for Health and Care Excellence (NICE). 2013. Process and Methods Guides No. 14.
   Google Scholar
• European Commission Enterprise And Industry Directorate-General. A guideline on summary of product characteristics (SmPC). [cited 2022 September 5]. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/product-information/how-prepare-review-summary-product-characteristics
   Google Scholar
• Dooms M, Killick J. Off-label use of medicines: the need for good practice guidelines. Int J Risk Saf Med. 2017;29(1–2):17–23.
   Google Scholar
• Food and Drug Administration. Regulations Regarding “Intended Uses” [cited 2021 dec 23]. Available at: https://www.federalregister.gov/documents/2021/08/02/2021-15980/regulations-regarding-intended-uses
   Google Scholar
• Declaration for Good Off-Label Use Practice. Promoting good practice for the off-label use of medicines: a harmonised European approach to prioritise patient safety. [cited 2022 May 10]. Available at: https://www.braincouncil.eu/golup/
   Google Scholar
• Leng B, Wang X. Research status on off-label use in appraisal for medical malpractice. J Forensic Med. 2018;34(2):171–174.
   Google Scholar
• Conroy S, Mcintyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonatal Med. 2005;10(2):115–122.
   Google Scholar
• Goločorbin Kon S, Iliković I, Mikov M. Reasons for and frequency of off-label drug use. Med Pregl. 2015;68(1–2):35–40.
   Google Scholar
• Dal PAN GJ. Monitoring the safety of medicines used off-label[J]. Clin Pharmacol Ther. 2012;91(5):787–795. 10.1038/clpt.2012.24.
   Google Scholar
• Le JEUNNE C, Billon N, Dandon A, et al. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice? Therapie. 2013;68(4):225–239.
   Google Scholar
• Schrier L, Hadjipanayis A, Stiris T, et al. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European academy of paediatrics and the European society for developmental perinatal and pediatric pharmacology. Eur J Pediatr. 2020;179(5):839–847.
   Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):924–939.
   Google Scholar
• Chinese Rheumatology Association. Chinese guideline for the diagnosis and treatment of rheumatoid arthritis. Chinese J Int Med. 2018;57(4):242–251.
   Google Scholar
• Rodon J, Soria JC, Berger R, et al. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015;26(8):1791–1798.
   Google Scholar
• The Central People’s Government of the People’s Republic of China. Civil code of the People’s Republic of Chian. [cited 2021 Dec 23]. Availabel online: https://epaper.gmw.cn/gmrb/html/2020-06/02/nw.D110000gmrb_20200602_7-01.htm
   Google Scholar
• Roth JA, Ballouz T, Kouyos RD, et al. Early off-label treatment during pandemics? A dilemma. Swiss Med Wkly. 2020;150:w20281.
   Google Scholar
• ZHENG Z, YANG M, WU J. Ethical off-label drug use: need for a rethink? Indian Pediatr. 2017;54(6):447–450.
   Google Scholar
• Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004 22;4(1):38.
   Google Scholar
• Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
   Google Scholar
• Zhang W, Xu J, Deng H. The system of grading the quality of medical evidence and the strength of recommendations: development and present situation. Chinese J of Evidence-Based Med. 2019;19(11):1373–1378.
   Google Scholar
• Tang H, Zhang T, Liu F, et al. An exploratory study on the method and process of evidence-base evaluation of off-label drug use. Chin Pharm J. 2015;50(19):1735–1738.
   Google Scholar
• Zhang W, Wang L, Zhao Y, et al. Assessment of off-label use of alprostadil injection by evidence-based medical approach. Chin J Hospital Pharm. 2017;37(2):177–180.
   Google Scholar
• Oxford Centre for Evidence-Based Medicine. Explanation of the 2011 OCEBM levels of evidence. [cited 2021 Dec 23]. Available at: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/explanation-of-the-2011-ocebm-levels-of-evidence
   Google Scholar
• Blanco-Reina E, Muñoz-García A, Cárdenas-Aranzana MJ, et al. Assessment of off-label prescribing: profile, evidence and evolution. Farm Hosp. 2017;41(4):458–469.
   Google Scholar
• Expert Committee on rheumatic Immunologic Drugs of Guangdong Pharmaceutical Society. Expert consensus on off-label drug instructions for rheumatic immune diseases (Part 1) - rheumatoid arthritis. Chinese J of Mod Appl Pharm. 2017;34(3):439–443.
   Google Scholar
• Expert Committee on rheumatic Immunologic Drugs of Guangdong Pharmaceutical Society. Expert consensus on super drug instructions for rheumatic immune diseases (Part 2) - systemic lupus erythematosus. Chinese J of Mod Appl Pharm. 2017;34(3):444–450.
   Google Scholar
• Wang Q, Dai L, Wu J. Expert consensus on off-label drug instructions for rheumatic immune diseases (Part 3) - ankylosing spondylitis. Chinese J of Mod Appl Pharm. 2017;34(3):451–457.
   Google Scholar
• Herrero Fernandez M, Molina Villaverde R, Arroyo Yustos M, et al. The off-label use of antineoplastics in oncology is limited but has notable scientific support in a university hospital setting. Front Pharmacol. 2019;10:1210.
   Google Scholar
• Yang J, Lin W, Chen Y. Off-label use of tamoxifen in a Chinese tertiary care hospital. Int J Clin Pharm. 2019;41(2):555–562.
   Google Scholar
• Wang D, Peng W, Jiao Y, et al. Research on classification management of off-label drug use on eviden based medicine. Chinese Hospital Manage. 2015;35(7):71–72.
   Google Scholar
• Stolbach AI, Mazer-Amirshahi M, Marino R, et al. ACMT position statement: off-label prescribing during COVID-19 pandemic. J Med Toxicol. 2020;16(3):342–345.
   Google Scholar
• Tobin JR. Use of pharmaceuticals ‘off-label’ in the neonate. Best Pract Res Clin Anaesthesiol. 2010;24(3):451–460.
   Google Scholar
• Tang Y, Gong W, Zhang B, et al. Off-label drug use in a child with McCune-Albright syndrome and its literature review. Chinese Pharm Affairs. 2019;33(1):90–94.
   Google Scholar
• Zhang B, Ru S, Mei D. Application of usage beyond foreign drug instructions in pediatrics. Pract Pharm Clin Remedies. 2008;05:270–272.
   Google Scholar
• Lat I, Micek S, Janzen J, et al. Off-label medication use in adult critical care patients. J Crit Care. 2011;26(1):89–94.
   Google Scholar
• Liu E, Smyth RL, Luo Z, et al. Rapid advice guidelines for management of children with COVID-19. Ann Transl Med. 2020;8(10):617.
   Google Scholar
• Casali PG, Bruzzi P, Bogaerts J, et al. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Ann Oncol. 2015;26(2):300–306.
   Google Scholar
• The Central People’s Government of the People’s Republic of China. Measures for the reporting and monitoring of adverse drug reactions. [cited 2021 Dec 23]. Available at: http://www.gov.cn/flfg/2011-05/24/content_1870110.htm
   Google Scholar
• Zhou Y, Ye G, Liu W, et al. Establishment and application of a grading evaluation model for adverse drug reaction severity. Chin J Hospital Pharm. 2021;41(20):2133–2137.
   Google Scholar
• Cheng J, Wang Z. Grading criteria for severity of adverse drug reaction damage and its bibliometric analysis. Evaluation and Analysis of Drug-Use in Hospitals of China. 2019;19(4):487–490.
   Google Scholar
• Zhang L, Tan L, Lu J. Expert consensus on off-label instruction medication. Adverse Drug React J. 2015;17(2):101–103.
   Google Scholar
• Wu H, Wu G. Strategy to address innovative off-label medication use in China: grading management. Eur J Clin Pharmacol. 2014;70(10):1271–1273.
   Google Scholar
• Chen J, Wang L, He G, et al. Exploration and practice of off-label instruction drug administration in our hospital. Tianjin Pharm. 2019;31(3):45–48.
   Google Scholar
• Huang L, Zhang L, Zeng L, et al. Practice and exploration of the construction of management system for off-label drug use in our hospital. China Pharm. 2019;30(1):1–5.
   Google Scholar
• Qi J, Ji Y, Li J. Case analysis of medical damage liability disputes related to off-lable drug use. Chinese J Pharmacoepidemiol. 2021;30(5):321–325.
   Google Scholar
• General Medical Council. Good practice in prescribing and managing medicines and devices. 2013. [cited 2021 Dec 23]. Available at: https://www.gmc-uk.org/-/media/documents/prescribing-guidance-updated-english-20210405_pdf-85260533.pdf
   Google Scholar
• Syed SA, Dixson BA, Constantino E, et al. The law and practice of off-label prescribing and physician promotion. J Am Acad Psychiatry Law. 2021;49(1):53–59.
   Google Scholar
• Vox F, Capron AM, Kraus MF, et al. Balancing burdens and benefits: ethical issues of off-label prescription pharmaceutical use. PMR. 2013;5(10):882–889.
   Google Scholar
• Wilkes M, Johns M. Informed consent and shared decision-making: a requirement to disclose to patients off-label prescriptions. PLoS Med. 2008;5(11):e223.
   Google Scholar
• Gazarian M, Kelly M, Mcphee JR, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544–548. 10.5694/j.1326-5377.2006.tb00689.x.
   Google Scholar
• Khamar B. Off-label use of medicines: medical research and medical practice. Indian J Ophthalmol. 2007;55:411–412.
   Google Scholar
• Mudur G. Indian medical association wants off-label prescribing. BMJ. 2004;328(7446):974.
   Google Scholar
• Oberoi SS. Regulating off-label drug use in India: the arena for concern. Perspect Clin Res. 2015;6(3):129–133.
   Google Scholar
• Congress of the United States. Federal food, drug, and cosmetic Act of 1938, P.L. No. 75–717, §52 Stat. 1040.
   Google Scholar
• Meadows WA, Hollowell BD. ‘Off-label’ drug use: an FDA regulatory term, not a negative implication of its medical use. Int J Impot Res. 2008;20(2):135–144.
   Google Scholar
• Lenk C, Duttge G. Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag. 2014;10:537–546.
   Google Scholar
• Cook RJ. Off-label drug use as a consent and health regulation issue in New Zealand. J Bioeth Inq. 2015;12(2):251–258.
   Google Scholar
• Akira A, Eisuke N, Aru A. Implementation of Japan’s first clinical research regulatory law: background, overview, and challenges. HEC Forum. 2019;31(4):283–294.
   Google Scholar
• Du B, Feng X, Shi X, et al. Pharmaceutical analysis of judicial precedents involving off-label drug use. Chin Pharm J. 2018;53(21):77–81.
   Google Scholar
• GJ Dal Pan. Monitoring the safety of medicines used off-label. Clin Pharmacol Ther. 2012;91(5):787–795.10.1038/clpt.2012.24
   Google Scholar
• Kramer MS, Hutchinson TA, Flegel KM, et al. Adverse drug reactions in general pediatric outpatients. J Pediatr. 1985;106(2):305–310.
   Google Scholar
• Lee JH, Byon HJ, Choi S, et al. Safety and efficacy of off-label and unlicensed medicines in children. J Korean Med Sci. 2018 19;33(37):e227.
   Google Scholar
• Smithburger PL, Buckley MS, Culver MA, et al. A multicenter evaluation of off-label medication use and associated adverse drug reactions in adult medical iCUs. Crit Care Med. 2015;43(8):1612–1621.
   Google Scholar
• Fabiano V, Mameli C, Zuccotti GV. Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future. Expert Opin Drug Saf. 2012;11(1):95–105.
   Google Scholar
• Impicciatore P, Mohn A, Chiarelli F, et al. Adverse drug reactions to off-label drugs on a paediatric ward: an Italian prospective pilot study. Paediatr Perinat Drug Ther. 2001;5:19–24.
   Google Scholar
• World Health Organization. Promoting safety of medicines for children. World Health Org. 2007‎ [cited 2021 Dec 23]. https://apps.who.int/iris/handle/10665/43697
   Google Scholar
• Rodwin MA. Rooting out institutional corruption to manage inappropriate off-label drug use. J Law Med Ethics. 2013;41(3):654–664.
   Google Scholar
• Cole LW, Kesselheim JC, Kesselheim AS. Ethical issues in new drug prescribing. J Bioeth Inq. 2012;9(1):77–83.
   Google Scholar
• Karande S, Gogtay NJ, Kshirsagar NA. Improving drug safety monitoring. Indian Pediatr. 2003;40(12):1167–1175.
   Google Scholar
• Czaja AS, Ross ME, Liu W, et al. Electronic health record (EHR) based postmarketing surveillance of adverse events associated with pediatric off-label medication use: a case study of short-acting beta-2 agonists and arrhythmias. Pharmacoepidemiol Drug Saf. 2018;27(7):815–822.
   Google Scholar
• Wang D. Active surveillance of adverse drug reaction and its development trend. Chinese Journal of Pharmacovigilance. 2015;10:600–602,610.
   Google Scholar
• When off label is off target. Nat Med. 2011;17(6):633.
   Google Scholar
• Coughlin M, Goldie CL, Tregunno D, et al. Enhancing metabolic monitoring for children and adolescents using second-generation antipsychotics. Int J Ment Health Nurs. 2018;27(3):1188–1198.
   Google Scholar
• Emmerich J, Dumarcet N, Lorence A. France’s new framework for regulating off-label drug use. N Engl J Med. 2012;367(14):1279–1281.
   Google Scholar
• Auffret M, Labreuche J, Duhamel A, et al. Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: an example with baclofen and alcohol dependence in France. Drug Saf. 2017;40(3):257–262.
   Google Scholar
• Santosh PJ, Bell L, Fiori F, et al. Pediatric antipsychotic use and outcomes monitoring. J Child Adolesc Psychopharmacol. 2017;27(6):546–554.
   Google Scholar
• Härmark L, van Grootheest K. Web-based intensive monitoring: from passive to active drug surveillance. Expert Opin Drug Saf. 2012;11(1):45–51.
   Google Scholar
• Eguale T, Winslade N, Hanley JA, et al. Enhancing pharmacosurveillance with systematic collection of treatment indication in electronic prescribing: a validation study in Canada. Drug Saf. 2010;33(7):559–567.
   Google Scholar
• Gerlach M, Egberts K, Dang SY, et al. Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry. Expert Opin Drug Saf. 2016;15(11):1477–1482.
   Google Scholar
• Castro-Pastrana LI, Carleton BC. Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge. J Popul Ther Clin Pharmacol. 2011;18:e76–88.
   Google Scholar
• Carnovale C, Brusadelli T, Zuccotti G, et al. The importance of monitoring adverse drug reactions in pediatric patients: the results of a national surveillance program in Italy. Expert Opin Drug Saf. 2014;13 Suppl 1:S1–8.
   Google Scholar
• Blumer JL. Off-Label uses of drugs in children. Pediatrics. 1999;104(3 Pt 2):598–602.
   Google Scholar
• Sang Y, Wu S, Lu C, et al. Problems and thoughts on reporting and monitoring of adverse drug reactions in drug manufacturers. Chinese Journal of Pharmacovigilance. 2019;16(4):215–218.
   Google Scholar
• Vargas-Rivas JE, Sabater-Hernández D, Calleja-Hernández MA, et al. Role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use. Int J Clin Pharm. 2011;33(5):719–721. author reply 722-3.
   Google Scholar
• Zheng Z, Zeng Y, Huang H. Pharmacists’ role in off-label drug use in China. Eur J Hosp Pharm. 2018;25(2):116.
   Google Scholar
• Skledar SJ, Corman SL, Smitherman T. Addressing innovative off-label medication use at an academic medical center. Am J Health Syst Pharm. 2015;72(6):469–477.
   Google Scholar
• Lao H, Wang Q, Yang M, et al. Study on clinical management methods and process of off-label drug use in guangdong general hospital. Chinese J of Evidence-Based Med. 2014;14(9):1025–1029.
   Google Scholar
• Yang M, Lao H, Zeng Y. Consensus of experts on the administration of off-label drug instructions in medical institutions. Chinese J of Mod Appl Pharm. 2017;34(3):436–438.
   Google Scholar
• Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J Law Med Ethics. 2009;37(3):476–86, 396.
   Google Scholar
• The Central People’s Government of the People’s Republic of China. Regulations on pharmaceutical administration of medical institutions. [cited2021 Dec 23]. Available at: http://www.gov.cn/zwgk/2011-03/30/content_1834424.htm
   Google Scholar
• Dooms M, Cassiman D, Simoens S. Off-label use of orphan medicinal products: a Belgian qualitative study. Orphanet J Rare Dis. 2016;11(1):144.
   Google Scholar
• Vostalova L, Mazelova J, Samek J, et al. Health technology assessment in evaluation of pharmaceuticals in the Czech Republic. Int J Technol Assess Health Care. 2017;33(3):339–344.
   Google Scholar
• Seidenschnur KEK, Dressler C, Weller K, et al. Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis. J Dtsch Dermatol Ges. 2017;15(11):1103–1109.
   Google Scholar
• Pauwels K, Huys I, Casteels M, et al. Market access of cancer drugs in European countries: improving resource allocation. Target Oncol. 2014;9(2):95–110.
   Google Scholar
• K HA, M SA, Briel M, et al. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO open. 2019;4(6):e000596.
   Google Scholar
• Teagarden JR, Dreitlein WB, Kourlas H, et al. Influence of pharmacy benefit practices on off-label dispensing of drugs in the United States. Clin Pharmacol Ther. 2012;91(5):943–945.
   Google Scholar
• Loblova O, Csanadi M, Ozieranski P, et al. Patterns of alternative access: unpacking the Slovak extraordinary drug reimbursement regime 2012-2016. Health Policy. 2019;123(8):713–720.
   Google Scholar
• Kang SY, Socal MP, Bai G, et al. Off-label coverage of high-cost drugs by independent charity patient assistance programs. J Gen Intern Med. 2021;36(2):555–556.
   Google Scholar
• Shimazawa R, Ikeda M. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications. Clin Ther. 2012;34(10):2104–2116.
   Google Scholar
• Neumann PJ, Bliss SK, Chambers JD. Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries. Health Aff (Millwood). 2012;31(4):700–708.
   Google Scholar
• Weissbach L, Riese J. Off-label use in oncology: an inexhaustible topic?[J]. Urologe A. 2006;45(11):1410, 1412–4.
   Google Scholar
• AIFA. Elenco farmaci erogabili a totale carico del S.S.N. AI SENSI della legge 648/96 E relative indicazioni terapeutiche (2019). [cited 2022 Dec 22]. Available at: https://www.aifa.gov.it/legge-648-96
   Google Scholar
• Sorenson C. Use of comparative effectiveness research in drug coverage and pricing decisions: a six country comparison. Issue brief (commonw fund). 2010;91:1–14.
   Google Scholar
• Council for Public Health and Health Care to the Minister of Health. 2006. Welfare, and sport. Sensible and sustainable care. [Internet]. The Hague: The Council. [cited 2021 Dec 23].Available at: http://www.rvz.net/uploads/docs/Sensible_and_sustainable_care.pdf
   Google Scholar
• Garau M, Mestre-Ferrandiz J Access mechanisms for orphan drugs: a comparative study of selected European countries. [Internet]. London: Office of Health Economics; 2009 Oct. OHE Research Briefing. [cited 2021 Dec 23]. Available at: http://www.raredisease.org.uk/documents/OHEBriefingOrphanDrugs.pdf
   Google Scholar
• Aguggia M, Cavallini M, Varetto L. Medical-legal issues in headache: penal and civil Italian legislation, working claims, social security, off-label prescription. Neurol Sci. 2006;27 Suppl 2:S198–202.
   Google Scholar
• Salvo I, Landoni G, Mucchetti M, et al. Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience. Paediatr Anaesth. 2014;24(6):625–631.
   Google Scholar
• Barbieri JS, St Claire K, Mostaghimi A, et al. Evaluation of clinical compendia used for medicare part D coverage determinations for off-label prescribing in dermatology. JAMA Dermatol. 2019;155(3):315–320.
   Google Scholar
• Centers for Medicare & Medicaid Services. Off-label use of colorectal cancer drugs allowed in select clinical trials. J Oncol Pract. 2005;1(1):12–14.
   Google Scholar
• Potter LM, Maldonado AQ, Lentine KL, et al. Transplant recipients are vulnerable to coverage denial under Medicare Part D. Am J Transplant. 2018;18(6):1502–1509.
   Google Scholar
• Rodwin MA. Rooting out institutional corruption to manage inappropriate off-label drug use. J Law Med Ethics. 2013;41(3):654–664. 10.1111/jlme.12075.
   Google Scholar
• Carroll J. Keeping the ball in bounds. Biotechnol Healthc. 2004;1(6):35–39.
   Google Scholar
• Todd AE. No need for more regulation payors and their role in balancing the cost and safety considerations of off-label prescriptions. Am J Law Med. 2011;37(2–3):422–443.
   Google Scholar
• American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol. 2006;24(19):3206–3208.
   Google Scholar
• Lerose R, Musto P, Aieta M. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. Eur J Clin Pharmacol. 2012;68(5):505–512.
   Google Scholar
• Nagai S, Ozawa K. Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects. Invest New Drugs. 2016;34(6):777–791.
   Google Scholar
• Perrone F, de Braud F, Labianca R, et al. Tackling off-label use of anticancer drugs. J Clin Oncol. 2012;30(22):2800. author reply 2801.
   Google Scholar
• National Medical Products Administration. Measures for the administration of drug registration. [cited 2021 Dec 23]. Available at: https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20200330180501220.html
   Google Scholar
• European medicines agency. Methotrexate containing medicinal products. [cited 2022 May 10]. Available at: https://www.ema.europa.eu/en/medicines/human/referrals/methotrexate-containing-medicinal-products
   Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–1123.
   Google Scholar